Artery Research
Volume 4, Issue 1 , Pages 1-6 , March 2010

Isolated systolic hypertension and the J-curve of cardiovascular disease risk

Received 4 January 2010 ,Revised 5 January 2010 ,Accepted 7 January 2010.

References 

  1. Stewart IMG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;I:861–865
  2. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;I:581–584
  3. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med. 2006;144:884–893
  4. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives – analysis based on NHANES III. Hypertension. 2001;37:869–874
  5. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, et al. Single versus combined blood pressure components and risk for cardiovascular disease. The Framingham Heart Study. Circulation. 2009;119:243–250
  6. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245–1249
  7. Klassen PS, Lowrie EG, Reddan DN, DeLomg ER, Coladonato JA, Szezech LA, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–1555
  8. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. Am J Epidemiol. 2007;166:824–831
  9. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy. JAMA. 2003;290:2805–2816
  10. Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 1991;265:3255–3264
  11. Fagard RH, Staessen JA, Lutgarde T, Celis HJ, Bulpitt CJ, de Leeuw PL, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167:1884–1891
  12. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907–913
  13. Kjeldsen SE, Sahlof B, Devereux RB, Julius S, Aurup P, Edelmen J, et al. Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) Substudy. JAMA. 2002;288:1491–1498
  14. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu S, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898
  15. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension. 2009;54:388–404
  16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  17. Reappraisal of European guidelines on hypertension management: A European Society of hypertension task force document. J Hypertens. 2009;27:2121–2158

☆ Based on the Donald A. McDonald Memorial Lecture given on October 9, 2009 at the Artery 9 meeting, Cambridge University, UK.

PII: S1872-9312(10)00003-7

doi: 10.1016/j.artres.2010.01.001

Artery Research
Volume 4, Issue 1 , Pages 1-6 , March 2010

Article Tools

* Image Usage & Resolution